Patients with GI Cancer
Deserve better treatment options,
Let's Give them one.

What is Electrochemotherapy?

When the uptake of chemotherapeutic drugs is enhanced by treating the tumour with pulsed electrical fields or ‘electroporation’ the therapy is referred to as ‘Electrochemotherapy’. The pulsed electrical field is delivered in seconds and causes pores to be formed in the tumour cells, allowing the drug far easier access inside the cancer cells where the drug can trigger the cells death. With electrochemotherapy unlike conventional chemotherapy the patient will receive just a single low dose of drug followed by the application of a pulsed electrical field to the tumour. While a second treatment can be administered this would typically be months apart. Your doctor will decide which type of drug to use based on your type of cancer.

Concept of ePORE® therapy: (1) Drug injection causes drug to surround tumour cell. (2) Electrical pulses are applied and this leads to pore formation in tumour cells and drug uptake. (3) The drug (can be a chemotherapy drug or molecule such as calcium) is absorbed by the tumour cell as the pores close. (4) The drug kills the cancer cells.

Patient Benefits

Improved Patient Experience

Delivered as a day-case procedure

ePORE® therapy can be delivered in minutes reducing patients time in the hospital or clinic

FAQ

ePORE® therapy with EndoVE® for GI cancers can be used for the treatment of solid tumours of the GI tract including oesophageal, gastric and colorectal cancer.

ePORE® therapy with EndoVE® is typically considered a day case treatment which requires a couple of hours in the hospital.  If treated with a light sedation, you should be able to leave the hospital or clinic the same day. If treated under general anaesthetic you will need to spend a longer period of time in the hospital in order to recover. The clinical team will explain the steps involved and whether treatment will be delivered as a day case or require a stay in hospital.

Clinical evidence is continuing to build on the use of EndoVE® for GI cancers and the potential side effects will vary depending on the nature and type (colorectal or oesophageal) of disease being treated. The clinical team will explain the risks involved and these should be carefully considered and understood. 
It might be necessary to have more than one session of ePORE® therapy and EndoVE® depending on the size, type and location of the tumour and/or if new tumours form

This will vary depending on the nature and type (colorectal or oesophageal) of disease being treated. The clinical team will explain how to manage your care in the days and weeks after a procedure. Should you have any concerns please contact the clinical team managing your care.